Skip to main content
Top
Published in: Annals of Hematology 5/2014

01-05-2014 | Original Article

Immune status of Fanconi anemia patients: decrease in T CD8 and CD56dim CD16+ NK lymphocytes

Authors: Graça A. Justo, Marco A. Bitencourt, Ricardo Pasquini, Morgana T. L. Castelo-Branco, Aline Almeida-Oliveira, Hilda Rachel Diamond, Vivian M. Rumjanek

Published in: Annals of Hematology | Issue 5/2014

Login to get access

Abstract

Fanconi anemia (FA), a rare genetic disease in which patients' life is compromised mainly by hematological abnormalities and cancer prone, seems to be affected by subtle immune cell irregularities. Knowing that FA presents developmental abnormalities and, based on recent reports, suggesting that natural killer (NK) CD56dim and NK CD56bright correspond to sequential differentiation pathways, we investigated if there were changes on the total number of NK cells and subsets as well as on T CD4 and T CD8 lymphocytes and their ratio. A large sample of FA patients (n = 42) was used in this work, and the results were correlated to clinical hematological status of these patients. Among FA patients, a decreased proportion of T CD8+ and NK CD56dimCD16+ cells were observed when compared to healthy controls as well as an imbalance of the subsets NK lymphocytes. Data suggest that FA patients might have a defective cytotoxic response due to the lower number of cytotoxic cells as well as impairment in the differentiation process of the NK cells subsets which may be directly related to impairment of the immune surveillance observed in these patients.
Literature
1.
go back to reference Joenje H, Patel KJ (2001) The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet 2:446–457PubMedCrossRef Joenje H, Patel KJ (2001) The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet 2:446–457PubMedCrossRef
4.
go back to reference Kennedy RD, D'Andrea AD (2005) The Fanconi anemia/BRCA pathway: new faces in the crowd. Genes Dev 19:2925–2940PubMedCrossRef Kennedy RD, D'Andrea AD (2005) The Fanconi anemia/BRCA pathway: new faces in the crowd. Genes Dev 19:2925–2940PubMedCrossRef
5.
go back to reference Li X, Yang Y, Yuan J, Hong P, Freie B, Orazi A, Haneline LS, Clapp DW (2004) Continuous in vivo infusion of interferon-gamma (IFN-γ) preferentially reduces myeloid progenitor numbers and enhances engraftment of syngeneic wild-type cells in Fancc−/− mice. Blood 104(4):1204–1209PubMedCrossRef Li X, Yang Y, Yuan J, Hong P, Freie B, Orazi A, Haneline LS, Clapp DW (2004) Continuous in vivo infusion of interferon-gamma (IFN-γ) preferentially reduces myeloid progenitor numbers and enhances engraftment of syngeneic wild-type cells in Fancc−/− mice. Blood 104(4):1204–1209PubMedCrossRef
6.
go back to reference Freie B, Li X, Ciccone SLM, Nawa K, Cooper S, Vogelweid C, Schantz L, Haneline LS, Orazi A, Broxmeyer HE, Lee S, Clapp DW (2003) Fanconi anemia type C and p53 cooperate in apoptosis and tumorigenesis. Blood 102(12):4146–4152PubMedCrossRef Freie B, Li X, Ciccone SLM, Nawa K, Cooper S, Vogelweid C, Schantz L, Haneline LS, Orazi A, Broxmeyer HE, Lee S, Clapp DW (2003) Fanconi anemia type C and p53 cooperate in apoptosis and tumorigenesis. Blood 102(12):4146–4152PubMedCrossRef
7.
go back to reference Hucl T, Gallmeier E (2011) DNA repair: exploiting the Fanconi anemia pathway as a potential therapeutic target. Physiol Res 60:453–465PubMed Hucl T, Gallmeier E (2011) DNA repair: exploiting the Fanconi anemia pathway as a potential therapeutic target. Physiol Res 60:453–465PubMed
8.
go back to reference Sejas DP, Rani R, Qiu Y, Zhang X, Fagerlie SR, Nakano H, Williams DA, Pang Q (2007) Inflammatory reactive oxygen species-mediated hemopoietic suppression in Fancc-deficient mice. J Immunol 178:5277–5287PubMedCentralPubMedCrossRef Sejas DP, Rani R, Qiu Y, Zhang X, Fagerlie SR, Nakano H, Williams DA, Pang Q (2007) Inflammatory reactive oxygen species-mediated hemopoietic suppression in Fancc-deficient mice. J Immunol 178:5277–5287PubMedCentralPubMedCrossRef
9.
go back to reference Ibáñez A, Río P, Casado JA, Bueren JA, Fernández-Luna JL, Pipaón C (2009) Elevated levels of IL-1β in Fanconi anaemia group A patients due to a constitutively active phosphoinositide 3-kinase-Akt pathway are capable of promoting tumour cell proliferation. Biochem J 422:161–170PubMedCrossRef Ibáñez A, Río P, Casado JA, Bueren JA, Fernández-Luna JL, Pipaón C (2009) Elevated levels of IL-1β in Fanconi anaemia group A patients due to a constitutively active phosphoinositide 3-kinase-Akt pathway are capable of promoting tumour cell proliferation. Biochem J 422:161–170PubMedCrossRef
10.
go back to reference Hersey P, Edwards A, Lewis R, Kemp A, Mcinnes J (1982) Deficient natural killer cell activity in a patient with Fanconi's anaemia and squamous cell carcinoma. Association with defect in interferon release. Clin Exp Immunol 48(1):205–212PubMedCentralPubMed Hersey P, Edwards A, Lewis R, Kemp A, Mcinnes J (1982) Deficient natural killer cell activity in a patient with Fanconi's anaemia and squamous cell carcinoma. Association with defect in interferon release. Clin Exp Immunol 48(1):205–212PubMedCentralPubMed
11.
12.
go back to reference Zaizov R, Matoth Y, Mamon Z (1978) Long term observations in children with Fanconi's anemia. In: Hibino S et al (eds) Aplastic anemia. University Park Press, Baltimore, p 243 Zaizov R, Matoth Y, Mamon Z (1978) Long term observations in children with Fanconi's anemia. In: Hibino S et al (eds) Aplastic anemia. University Park Press, Baltimore, p 243
13.
go back to reference Pederson FK, Hertz H, Lundsteen C, Platz P, Thomsen M (1977) Indications of primary immune deficiency in Fanconi's anaemia. Acta Paediatr Scand 66:745CrossRef Pederson FK, Hertz H, Lundsteen C, Platz P, Thomsen M (1977) Indications of primary immune deficiency in Fanconi's anaemia. Acta Paediatr Scand 66:745CrossRef
14.
go back to reference Myers KC, Bleesing JJ, Davies SM, Zhang X, Martin LJ, Mueller R, Harris RE, Filipovich AH, Kovacic MB, Wells SI, Parinda A, Mehta PA (2011) Impaired immune function in children with Fanconi anaemia. Br J Haematol 154:234–240PubMedCrossRef Myers KC, Bleesing JJ, Davies SM, Zhang X, Martin LJ, Mueller R, Harris RE, Filipovich AH, Kovacic MB, Wells SI, Parinda A, Mehta PA (2011) Impaired immune function in children with Fanconi anaemia. Br J Haematol 154:234–240PubMedCrossRef
15.
go back to reference Korthof ET, Svahn J, Peffault de Latour R et al (2013) Immunological profile of Fanconi anemia: a multicentric retrospective analysis of 61 patients. Am J Hematol 88(6):472–476PubMedCrossRef Korthof ET, Svahn J, Peffault de Latour R et al (2013) Immunological profile of Fanconi anemia: a multicentric retrospective analysis of 61 patients. Am J Hematol 88(6):472–476PubMedCrossRef
16.
go back to reference Chávez-Galán L, Arenas-Del Angel MC, Zenteno E, Chávez R, Lascurain R (2009) Cell death mechanisms induced by cytotoxic lymphocytes. Cel Mol Immunol 6(1):15–25CrossRef Chávez-Galán L, Arenas-Del Angel MC, Zenteno E, Chávez R, Lascurain R (2009) Cell death mechanisms induced by cytotoxic lymphocytes. Cel Mol Immunol 6(1):15–25CrossRef
17.
go back to reference Cooley S, Weisdorf DS (2010) Natural killer cells and tumor control. Cur Opin Hematol 17:514–521CrossRef Cooley S, Weisdorf DS (2010) Natural killer cells and tumor control. Cur Opin Hematol 17:514–521CrossRef
18.
go back to reference Penack O, Gentilini C, Fischer L, Asemissen AM, Scheibenbogen C, Thiel E, Uharek L (2005) CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets. Leukemia 19:835–840PubMedCrossRef Penack O, Gentilini C, Fischer L, Asemissen AM, Scheibenbogen C, Thiel E, Uharek L (2005) CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets. Leukemia 19:835–840PubMedCrossRef
19.
go back to reference Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L (2008) NK cells at the interface between innate and adaptive immunity. Cell Death Diff 15:226–233 (review)CrossRef Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L (2008) NK cells at the interface between innate and adaptive immunity. Cell Death Diff 15:226–233 (review)CrossRef
21.
go back to reference Tarazona R, Casado JG, Delarosa O et al (2002) Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals. J Clin Immunol 22(3):176–183PubMedCrossRef Tarazona R, Casado JG, Delarosa O et al (2002) Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals. J Clin Immunol 22(3):176–183PubMedCrossRef
22.
go back to reference Hong HS, Eberhard JM, Keudel P et al (2010) Phenotypically and functionally distinct subsets contribute to the expansion of CD56−/CD16+ natural killer cells in HIV infection. AIDS 24(12):1823–1834PubMedCrossRef Hong HS, Eberhard JM, Keudel P et al (2010) Phenotypically and functionally distinct subsets contribute to the expansion of CD56−/CD16+ natural killer cells in HIV infection. AIDS 24(12):1823–1834PubMedCrossRef
23.
go back to reference Schepis D, Gunnarsson I, Eloranta ML et al (2009) Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology 126(1):140–146PubMedCentralPubMedCrossRef Schepis D, Gunnarsson I, Eloranta ML et al (2009) Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology 126(1):140–146PubMedCentralPubMedCrossRef
24.
go back to reference Saraste M, Irjala H, Airas L (2007) Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci 28(3):121–126PubMedCrossRef Saraste M, Irjala H, Airas L (2007) Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci 28(3):121–126PubMedCrossRef
25.
go back to reference Lee S, Watson MW, Flexman JP, Cheng W, Hammond T, Price P (2010) Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy. J Med Virol 82(4):568–574PubMedCrossRef Lee S, Watson MW, Flexman JP, Cheng W, Hammond T, Price P (2010) Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy. J Med Virol 82(4):568–574PubMedCrossRef
26.
go back to reference Auerbach AD, Rogatko A, Schroeder-Kurth TM (1989) International Fanconi Anemia Registry: relation of clinical symptoms to diepoxybutane sensitivity. Blood 73:391–396PubMed Auerbach AD, Rogatko A, Schroeder-Kurth TM (1989) International Fanconi Anemia Registry: relation of clinical symptoms to diepoxybutane sensitivity. Blood 73:391–396PubMed
27.
go back to reference Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22(11):633–640PubMedCrossRef Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22(11):633–640PubMedCrossRef
28.
go back to reference Baruque GA, Bitencourt MA, Pasquini R, Castelo-Branco MTL, Llerena JRJC, Rumjanek VM (2005) Apoptosis and expression of anti- and pro-apoptotic proteins in peripheral blood mononuclear cells of Fanconi anaemia patients: a study of 73 cases. Eur J Haematol 75:384–390PubMedCrossRef Baruque GA, Bitencourt MA, Pasquini R, Castelo-Branco MTL, Llerena JRJC, Rumjanek VM (2005) Apoptosis and expression of anti- and pro-apoptotic proteins in peripheral blood mononuclear cells of Fanconi anaemia patients: a study of 73 cases. Eur J Haematol 75:384–390PubMedCrossRef
29.
go back to reference Castello G, Gallo C, Napolitano M, Ascierto PA (1998) Immunological phenotype analysis of patients with Fanconi's anaemia and their family members. Acta Haematol 100(1):39–43PubMedCrossRef Castello G, Gallo C, Napolitano M, Ascierto PA (1998) Immunological phenotype analysis of patients with Fanconi's anaemia and their family members. Acta Haematol 100(1):39–43PubMedCrossRef
31.
32.
go back to reference Almeida-Oliveira A, Smith-Carvalho M, Porto LC, Cardoso-Oliveira J, Ribeiro AS, Falcão RR, Abdelhay E, Bouzas LF, Thuler LCS, Ornellas MH, Diamond HR (2011) Age-related changes in natural killer cell receptors from childhood through old age. H Immunol 72:319–329CrossRef Almeida-Oliveira A, Smith-Carvalho M, Porto LC, Cardoso-Oliveira J, Ribeiro AS, Falcão RR, Abdelhay E, Bouzas LF, Thuler LCS, Ornellas MH, Diamond HR (2011) Age-related changes in natural killer cell receptors from childhood through old age. H Immunol 72:319–329CrossRef
33.
go back to reference Froom P, Aghai E, Dobinsky JB, Quitt M, Lahat N (1987) Reduced natural killer activity in patients with Fanconi's anemia and in family members. Leuk Res 11(2):197–199PubMedCrossRef Froom P, Aghai E, Dobinsky JB, Quitt M, Lahat N (1987) Reduced natural killer activity in patients with Fanconi's anemia and in family members. Leuk Res 11(2):197–199PubMedCrossRef
34.
go back to reference Lebbé C, Pinquier L, Rybojad M, Chomienne C, Ochonisky S, Miclea JM, Gluckman E, Morel P (1993) Fanconi's anaemia associated with multicentric Bowen's disease and decreased NK cytotoxicity. Br J Dermatol 129(5):615–618PubMedCrossRef Lebbé C, Pinquier L, Rybojad M, Chomienne C, Ochonisky S, Miclea JM, Gluckman E, Morel P (1993) Fanconi's anaemia associated with multicentric Bowen's disease and decreased NK cytotoxicity. Br J Dermatol 129(5):615–618PubMedCrossRef
36.
go back to reference Chan A, Hong DL, Atzberger A, Kollnberger S, Filer AD, Buckley CD, McMichael A, Enver T, Bowness P (2007) CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol 179:89–94PubMedCrossRef Chan A, Hong DL, Atzberger A, Kollnberger S, Filer AD, Buckley CD, McMichael A, Enver T, Bowness P (2007) CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol 179:89–94PubMedCrossRef
37.
go back to reference Loza MJ, Perussia B (2004) The IL-12 signature: NK cell terminal CD56+high stage and effector functions. J Immunol 172:88–96PubMedCrossRef Loza MJ, Perussia B (2004) The IL-12 signature: NK cell terminal CD56+high stage and effector functions. J Immunol 172:88–96PubMedCrossRef
38.
go back to reference de Matos CT, Berg L, Michaëlsson J, Fellander-Tsai L, Kärre K, Söderström K (2007) Activating and inhibitory receptors on synovial fluid natural killer cells of arthritis patients: role of CD94/NKG2A in control of cytokine secretion. Immunology 122:291–301PubMedCentralPubMedCrossRef de Matos CT, Berg L, Michaëlsson J, Fellander-Tsai L, Kärre K, Söderström K (2007) Activating and inhibitory receptors on synovial fluid natural killer cells of arthritis patients: role of CD94/NKG2A in control of cytokine secretion. Immunology 122:291–301PubMedCentralPubMedCrossRef
39.
go back to reference Belisle JA, Gubbels JA, Raphael CA et al (2007) Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology 122:418–429PubMedCentralPubMedCrossRef Belisle JA, Gubbels JA, Raphael CA et al (2007) Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology 122:418–429PubMedCentralPubMedCrossRef
40.
go back to reference Katchar K, Söderström K, Wahlstrom J, Eklund A, Grunewald J (2005) Characterisation of natural killer cells and CD56+ T-cells in sarcoidosis patients. Eur Respir J 26:77–85PubMedCrossRef Katchar K, Söderström K, Wahlstrom J, Eklund A, Grunewald J (2005) Characterisation of natural killer cells and CD56+ T-cells in sarcoidosis patients. Eur Respir J 26:77–85PubMedCrossRef
41.
go back to reference Inngjerdingen M, Kveberg L, Naper C, Vaage JT (2011) Natural killer cell subsets in man and rodents. Tissue Antigens 78:81–88PubMedCrossRef Inngjerdingen M, Kveberg L, Naper C, Vaage JT (2011) Natural killer cell subsets in man and rodents. Tissue Antigens 78:81–88PubMedCrossRef
42.
go back to reference Takahashi E, Kuranaga N, Satoh K, Habu Y, Shinomiya N, Asano T, Seki S, Hayakawa M (2007) Induction of CD16+CD56bright NK cells with antitumour cytotoxicity not only from CD16−CD56bright NK cells but also from CD16−CD56dim NK cells. Scand J Immunol 65:126–138PubMedCrossRef Takahashi E, Kuranaga N, Satoh K, Habu Y, Shinomiya N, Asano T, Seki S, Hayakawa M (2007) Induction of CD16+CD56bright NK cells with antitumour cytotoxicity not only from CD16CD56bright NK cells but also from CD16CD56dim NK cells. Scand J Immunol 65:126–138PubMedCrossRef
43.
go back to reference Rosselli F, Sanceau J, Gluckman E, Wietzerbin J, Moustacchi E (1994) Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia: II. In vitro and in vivo spontaneous overproduction of tumor necrosis factor α. Blood 83:1216–1225PubMed Rosselli F, Sanceau J, Gluckman E, Wietzerbin J, Moustacchi E (1994) Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia: II. In vitro and in vivo spontaneous overproduction of tumor necrosis factor α. Blood 83:1216–1225PubMed
44.
go back to reference Rathbun RK, Faulkner GR, Ostroski MH, Christianson TA, Hughes G, Jones G, Cahn R, Maziarz R, Royle G, Keeble W, Heinrich MC, Grompe M, Tower PA, Bagby GC (1997) Inactivation of the Fanconi anemia group C gene augments interferon-γ-induced apoptotic response in hematopoietic cells. Blood 90:974–985PubMed Rathbun RK, Faulkner GR, Ostroski MH, Christianson TA, Hughes G, Jones G, Cahn R, Maziarz R, Royle G, Keeble W, Heinrich MC, Grompe M, Tower PA, Bagby GC (1997) Inactivation of the Fanconi anemia group C gene augments interferon-γ-induced apoptotic response in hematopoietic cells. Blood 90:974–985PubMed
45.
go back to reference Pilonetto DV, Pereira NF, Bitencourt MA, Magdalena NIR, Vieira ER, Veiga LBA, Cavalli IJ, Ribeiro RC, Pasquini R (2009) FANCD2 Western blot as a diagnostic tool for Brazilian patients with Fanconi anemia. Br J Med Biol Res 42:237–243CrossRef Pilonetto DV, Pereira NF, Bitencourt MA, Magdalena NIR, Vieira ER, Veiga LBA, Cavalli IJ, Ribeiro RC, Pasquini R (2009) FANCD2 Western blot as a diagnostic tool for Brazilian patients with Fanconi anemia. Br J Med Biol Res 42:237–243CrossRef
46.
go back to reference Levitus M, Rooimans MA, Steltenpool J, Cool NF, Oostra AB, Mathew CG et al (2004) Heterogeneity in Fanconi anemia: evidence for 2 new genetic subtypes. Blood 103:2498–2503PubMedCrossRef Levitus M, Rooimans MA, Steltenpool J, Cool NF, Oostra AB, Mathew CG et al (2004) Heterogeneity in Fanconi anemia: evidence for 2 new genetic subtypes. Blood 103:2498–2503PubMedCrossRef
47.
go back to reference Shimamura A (2006) Inherited bone marrow failure syndromes: molecular features. Hematology Am Soc Hematol Educ Program 63–71 Shimamura A (2006) Inherited bone marrow failure syndromes: molecular features. Hematology Am Soc Hematol Educ Program 63–71
Metadata
Title
Immune status of Fanconi anemia patients: decrease in T CD8 and CD56dim CD16+ NK lymphocytes
Authors
Graça A. Justo
Marco A. Bitencourt
Ricardo Pasquini
Morgana T. L. Castelo-Branco
Aline Almeida-Oliveira
Hilda Rachel Diamond
Vivian M. Rumjanek
Publication date
01-05-2014
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 5/2014
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-013-1953-4

Other articles of this Issue 5/2014

Annals of Hematology 5/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.